糖尿病

订阅

MedSci主页 / 所有栏目 / 糖尿病

Diabetes：代谢产物与胰岛素抵抗密切相关

2012-05-06 佚名 糖尿病手机报第11期

糖尿病代谢产物胰岛素抵抗
关注

　　芬兰一项研究报告，氨基酸、葡萄糖合成中间产物、酮体、脂肪酸等20种代谢物与胰岛素抵抗相关性。研究4月17日在线发表于《糖尿病》（Diabetes）杂志。 　　该研究纳入7098名芬兰人，对胰岛素抵抗相关代谢产物进行分析。支链和芳香族氨基酸、糖异生中间产物、酮体以及脂肪酸成分和饱和度与稳态模型胰岛素抵抗指数（HOMA-IR）相关，亮氨酸、异亮氨酸、缬氨酸、酪氨酸在异常肥胖的女性中显著增多。与1

　　芬兰一项研究报告，氨基酸、葡萄糖合成中间产物、酮体、脂肪酸等20种代谢物与胰岛素抵抗相关性。研究4月17日在线发表于《糖尿病》（Diabetes）杂志。

　　该研究纳入7098名芬兰人，对胰岛素抵抗相关代谢产物进行分析。支链和芳香族氨基酸、糖异生中间产物、酮体以及脂肪酸成分和饱和度与稳态模型胰岛素抵抗指数（HOMA-IR）相关，亮氨酸、异亮氨酸、缬氨酸、酪氨酸在异常肥胖的女性中显著增多。与12种代谢产物有关的GCKR变异亦与HOMA-IR相关。在年轻人群中，除了反映肥胖和脂质异常之外的其他代谢标志物，反映了胰岛素抵抗的程度。



    

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1900947, encodeId=55df190094ecd, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 24 04:06:00 CST 2012, time=2012-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749343, encodeId=f5ea1e49343f7, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed Jun 06 21:06:00 CST 2012, time=2012-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636498, encodeId=810d163649825, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Nov 08 14:06:00 CST 2012, time=2012-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759136, encodeId=82181e5913616, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jun 03 23:06:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513429, encodeId=af5d151342905, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon May 07 15:06:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
    2012-10-24 木头人513

    #Diabetes#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1900947, encodeId=55df190094ecd, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 24 04:06:00 CST 2012, time=2012-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749343, encodeId=f5ea1e49343f7, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed Jun 06 21:06:00 CST 2012, time=2012-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636498, encodeId=810d163649825, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Nov 08 14:06:00 CST 2012, time=2012-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759136, encodeId=82181e5913616, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jun 03 23:06:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513429, encodeId=af5d151342905, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon May 07 15:06:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
    2012-06-06 baoya

    #胰岛#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1900947, encodeId=55df190094ecd, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 24 04:06:00 CST 2012, time=2012-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749343, encodeId=f5ea1e49343f7, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed Jun 06 21:06:00 CST 2012, time=2012-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636498, encodeId=810d163649825, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Nov 08 14:06:00 CST 2012, time=2012-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759136, encodeId=82181e5913616, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jun 03 23:06:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513429, encodeId=af5d151342905, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon May 07 15:06:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
    2012-11-08 ms9608593228839890

    #DIA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1900947, encodeId=55df190094ecd, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 24 04:06:00 CST 2012, time=2012-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749343, encodeId=f5ea1e49343f7, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed Jun 06 21:06:00 CST 2012, time=2012-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636498, encodeId=810d163649825, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Nov 08 14:06:00 CST 2012, time=2012-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759136, encodeId=82181e5913616, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jun 03 23:06:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513429, encodeId=af5d151342905, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon May 07 15:06:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
    2012-06-03 ms5439512287675881

    #BET#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1900947, encodeId=55df190094ecd, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 24 04:06:00 CST 2012, time=2012-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749343, encodeId=f5ea1e49343f7, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed Jun 06 21:06:00 CST 2012, time=2012-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636498, encodeId=810d163649825, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Nov 08 14:06:00 CST 2012, time=2012-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759136, encodeId=82181e5913616, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jun 03 23:06:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513429, encodeId=af5d151342905, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon May 07 15:06:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
    2012-05-07 124987c6m39暂无昵称

    #代谢产物#

    0

相关资讯

2型糖尿病患者下肢神经传导异常率高于上肢

　　最近，南京军区南京总医院神经内科的研究人员的一项研究显示，尽管受检时血糖控制良好，但依然有周围神经电生理异常变化。2型糖尿病患者下肢神经传导异常率高于上肢，尤以运动神经明显。病程是糖尿病周围神经损害的危险因素，随着病程增加神经传导异常率和损伤严重程度增高。该研究发表于2012年第3期《中风与神经疾病杂志》。 　　该研究旨在探讨2型糖尿病患者周围神经病变(DPN)的神经电生理特点及其与病程的关

ADA官方杂志精选中文版近期出版

　　美国糖尿病学会（ADA）出版有《糖尿病》（Diabetes）、《糖尿病护理》（Diabetes Care）、《临床糖尿病》（Clinical Diabetes）和《糖尿病谱》（Diabetes Spectrum）4本官方杂志，近日ADA首次为中国糖尿病学界设立上述杂志精选中文版《American Diabetes Association Journals In Focus》，以向我国传播和介绍

换用不同种类胰岛素血糖改善情况和低血糖风险无差异

　　近期一项名为SWING的多国研究报告，在2型糖尿病患者中，从短效人胰岛素换用速效胰岛素类似物（H-A）后，糖尿病相关直接医疗费用略增加，而反之（A-H）费用则略降低。但两种换药方法在改善HbA1c和降低低血糖风险等方面均无明显差异。研究4月9日在线发表于《糖尿病研究与临床实践》（Diabetes Res Clin Pract）。 　　该项在欧洲9个国家开展的前瞻性观察性研究纳入2389例2型

共患抑郁的2型糖尿病患者3~5年内痴呆风险倍增

　　美国一项研究显示，患有2型糖尿病(T2DM)的患者，若共患抑郁，则痴呆风险增加。论文发表于《普通精神病学文献》[Arch Gen Psychiatry 2012，69（4）：410]。 　　研究纳入30~75岁糖尿病患者19239例，根据患者健康问卷8、国际疾病分类第9版（ICD-9）和（或）在基线前12个月使用抗抑郁药情况评估患者共患抑郁情况。为排除抑郁为痴呆

BMJ：糖尿病问诊技巧培训未能改善1型糖尿病儿童血糖控制（DEPICTED研究）

　　英国研究者进行的一项聚类随机对照临床试验（DEPICTED研究）表明，通过简单的集体培训问诊技巧的方式不能改善糖尿病专科诊所儿童的血糖控制。该研究结果4月26日发表于《英国医学杂志》（BMJ）。 　　研究者为了评价面向儿科糖尿病团队的问诊技巧培训项目对血糖控制的效果，在26个英国二级和三级儿科糖尿病护理机构进行了此项研究，干预组培训13个团队79名医生（涉及359例年龄为4~15岁的1型糖尿

NEJM：二甲双胍加用罗格列酮改善年轻2型糖尿病患者血糖控制（TODAY研究）

　　TODAY研究表明，在约半数儿童和青少年2型糖尿病患者中，二甲双胍单药治疗与长期血糖控制有关。加用罗格列酮，而不是强化生活方式干预，优于二甲双胍单药治疗。该研究4月29日在线发表于《新英格兰医学杂志》（N Engl J Med）。 　　研究者纳入年龄为10~17岁接受二甲双胍治疗的新发2型糖尿病青少年患者，比较了3种治疗方案的疗效：继续使用二甲双胍单药治疗、二甲